Journal article

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, H Wasan, F Ciardiello, F Loupakis, YS Hong, N Steeghs, TK Guren, H-T Arkenau, P Garcia-Alfonso, P Pfeiffer, S Orlov, S Lonardi, E Elez, T-W Kim, JHM Schellens Show all

New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2019


BACKGROUND: Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling. METHODS: In this open-label, phase 3 trial, we enrolled 665 patients with BRAF V600E-mutated metastatic colorectal cancer who had had disease progression after one or two previous regimens. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investig..

View full abstract